Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
Commentary|Videos|April 23, 2026
COA 2026: Turning Policy Into Practice: Why Advocacy Matters in Community Oncology
Advertisement
In this Community Oncology Alliance (COA) pre-conference interview with Pharmacy Times, Nick Ferreyros discusses the importance of making health policy relevant by connecting it directly to patient care and clinical practice. He highlights new data from collaboration with Flatiron Health showing strong outcomes in community oncology, helping to challenge outdated perceptions. Ferreyros also warns of key policy threats, including the Inflation Reduction Act, and ongoing challenges with pharmacy benefit managers that may impact care delivery. He emphasizes that provider advocacy is essential to driving change and protecting access to care. You can view more coverage from COA
Advertisement
Related to this article
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Nationwide Danish data presented at EASD 2026 link a widening cancer gap in type 2 diabetes largely to obesity-related cancers.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
2
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
3
Dostarlimab Receives FDA Accelerated Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
4
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
5